Afternoon exercise group had greatest reduction in HbA1c at year 1 among adults with overweight or obesity and type 2 diabetes.

Incidence of primary end point ranged from reduction of about 2.8% to increase of about 0.5%.

The inequality aversion parameter would need to be 0.90 for gene therapy to be preferred per distributional cost-effectiveness analysis standards.

In study involving 40 patients, high patient satisfaction was observed and no adverse events were recorded

Findings seen in patients with ischemic stroke without occlusion of large or medium-sized vessels, at least one moderately to severely weak limb.

Unapproved products are unlikely to actually have the impact they claim and may cause bad reactions.

When importing drugs, the FDA stressed that regulators carefully assess product quality and manufacturing processes to ensure patient safety.

The approval was based on data from the randomized, double-blind, placebo-controlled phase 4 CONFIRM-HF trial.

Nirogacestat is an oral, selective, small molecule gamma secretase inhibitor that works by blocking proteolytic activation of Notch receptors.

Prescribers must become certified in the Lumryz REMS to prescribe the medication.